Voriconazole: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
Line 1: | Line 1: | ||
== Dose Adjustment Guidelines == |
== Dose Adjustment Guidelines == |
||
{| class="wikitable" |
|||
{| |
|||
! Trough (mcg/mL) |
! Trough (mcg/mL) |
||
! Recommendation |
! Recommendation |
Revision as of 16:12, 9 September 2019
Dose Adjustment Guidelines
Trough (mcg/mL) | Recommendation |
---|---|
0.0 to 0.6 | Increase dose by 100 mg and recheck trough on day 5 of new regimen |
0.7 to 0.9 | Increase dose by 50 mg and recheck trough on day 5 of new regimen |
1.0 to 4.0 | At target, no dose adjustment needed |
4.1 to 5.5 | Decrease dose by 50 mg and recheck trough on day 5 of new regimen |
5.6 to 7.9 | Hold dose. Follow daily trough levels, then restart when trough is ≤2.5 at a dose decreased by 100 mg. Recheck trough on day 5 of new regimen. |
≥8.0 | Hold dose. Follow daily trough levels, then restart when trough is ≤2.5 at a dose decreased by 50%. Recheck trough level on day 5 of new regimen. |
Further Reading
- Voriconazole Dose Modification Guideline to Optimize Therapeutic Levels in Patients With Hematologic Malignancies. Open Forum Infect Dis. 2015(2)S1:810.
References
- ^ Romeo-Gabriel Mihăilă. Voriconazole and the liver. World Journal of Hepatology. 2015;7(13):1828. doi:10.4254/wjh.v7.i14.1828.
- ^ Taotao Wang, Liyan Miao, Hua Shao, Xiaohua Wei, Miao Yan, Xiaocong Zuo, Jun Zhang, Xin Hai, Guangjun Fan, Wei Wang, Linlin Hu, Jian Zhou, Yichang Zhao, Yueliang Xie, Jingjing Wang, Sixun Guo, Liu Jin, Hao Li, Hui Liu, Quanfang Wang, Jiaojiao Chen, Sihan Li, Yalin Dong. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study. International Journal of Antimicrobial Agents. 2022;60(5-6):106692. doi:10.1016/j.ijantimicag.2022.106692.